Combined locoregional-immunotherapy for liver cancer
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Locoregional therapies are commonly used to treat patients with hepatocellular carcinoma. It has been noted for many years that locoregional therapies may have additional systemic effects other than simple tumor elimination. Immunological “side effects” have been described in response to locoregional therapies in animal studies and also in patients. With the advent of immunotherapy for hepatocellular carcinoma, there is an increasing interest in understanding how immunotherapy may be best combined with locoregional therapies. Here we provide a compact summary of answered and unanswered questions in this field including: What animal model is best suited to test combined immune-locoregional treatments? How does tumor cell death affect immune responses? What type of immune responses have been observed in patients treated with different types of locoregional therapies? What can be surmised from results of a first study testing the combination of locoregional therapy with immune checkpoint blockade? Finally, we provide an outlook of research issues and needs in order to advance this rapidly growing field bridging interventional radiology and cancer immunology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Immunogenic Cell Death in Cancer Therapy
Kroemer, G., Galluzzi, L., Kepp, O., & Zitvogel, L. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-100008 · Cited by 3,303 · cited 1×
“Immunogenic cell death (ICD) involves release of calreticulin and other endoplasmic reticulum proteins at the cell surface, the secretion of ATP during the blebbing phase of apoptosis, and the cell death–associated release of the non-histone chromatin protein high-mobility group box 1 (HMGB1) facilitating recruitment…”
BackgroundImmunological effects of conventional chemotherapy and targeted anticancer agents
Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.10.012 · Cited by 1,530
Hoechst, B., Ormandy, L. A., Ballmaier, M., Lehner, F., Krüger, C., Manns, M. P., Greten, T. F., & Korangy, F. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.020 · Cited by 793
Self-citationNecroptosis microenvironment directs lineage commitment in liver cancer
Seehawer, M., Heinzmann, F., D’Artista, L., Harbig, J., Roux, P.-F., Hoenicke, L., Dang, H., Klotz, S., Robinson, L., Doré, G., et al. (2018) · Nature · doi:10.1038/s41586-018-0519-y · Cited by 406 · cited 1×
“Pharmacological or genetic suppression of necroptosis revert the necroptosis-dependent cytokine microenvironment and switches ICC to HCC (20).”
Background
Cited by
Immunotherapies for hepatocellular carcinoma
Llovet, J. M., Castet, F., Heikenwalder, M., Maini, M. K., Mazzaferro, V., Pinato, D. J., Pikarsky, E., Zhu, A. X., & Finn, R. S. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00573-2 · Cited by 1,843
Hack, S. P., Zhu, A. X., & Wang, Y. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.598877 · Cited by 286
Turning up the heat on non-immunoreactive tumours: opportunities for clinical development
Ochoa de Olza, M., Navarro Rodrigo, B., Zimmermann, S., & Coukos, G. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30234-5 · Cited by 256
Metadata
- Authors
- Greten, T. F., Mauda-Havakuk, M., Heinrich, B., Korangy, F., & Wood, B. J.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2019-05
- Volume
- 70
- Issue
- 5
- Pages
- 999-1007
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W2911646196
- Cited by
- 212
- References
- 4
- FWCI
- 14.77
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Combined locoregional-immunotherapy for liver cancer. https://app.cochat.ai/papers/10.1016/j.jhep.2019.01.027
- The paper
- Greten, T. F., Mauda-Havakuk, M., Heinrich, B., Korangy, F., & Wood, B. J. (2019). Combined locoregional-immunotherapy for liver cancer. Journal of Hepatology. https://doi.org/10.1016/j.jhep.2019.01.027
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.